Dynamics of raltegravir resistance profile in an HIV type 2-infected patient

AIDS Research and Human Retroviruses

Volumn 25, Issue 8, 2009, Pages 843-847

  Xu, Li ^a   Anderson, Jane ^b   Garrett, Nigel ^b   Ferns, Bridget ^c   Wildfire, Adrian ^d   Cook, Pamela ^a   Workman, Judith ^a   Graham, Susan ^a   Smit, Erasmus ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^b HOMERTON UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; DARUNAVIR PLUS RITONAVIR; INTEGRASE; RALTEGRAVIR; ZIDOVUDINE;

ARTICLE; CD4 LYMPHOCYTE COUNT; DYNAMICS; FOLLOW UP; GENETIC RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 2; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT FAILURE; UNINDEXED SEQUENCE; VIRUS LOAD;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; HIV INFECTIONS; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-2; PYRROLIDINONES; RNA, VIRAL; SEQUENCE ANALYSIS, RNA; TREATMENT FAILURE;

EID: 70349221276     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.2009.0039     Document Type: Article

References (28)

1. Billich A: S-1360 Shionogi-GlaxoSmithKline. Curr Opin Investig Drugs 2003;4(2):206-209.
2. Hazuda DJ, Felock P, Witmer M, et al.: Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells. Science 2000;287(5453):646-650.
3. Hazuda DJ, Anthony NJ, Gomez RP, et al.: A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase. Proc Natl Acad Sci USA 2004;101(31):11233-11238.
4. Sato M, Motomura T, Aramaki H, et al.: Novel HIV-1 integrase inhibitors derived from quinolone antibiotics. J Med Chem 2006;49(5):1506-1508.
5. DeJesus E, Berger D, Markowitz M, et al.: Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 ( JTK-303) in treatment-naive and treatment-experienced patients. J Acquir Immune Defic Syndr 2006;43(1):1-5.
6. Grinsztejn B, Nguyen BY, Katlama C, et al.: Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: A phase II randomised controlled trial. Lancet 2007; 369(9569):1261-1269.
7. Garrett N, Xu L, Smit E, et al.: Raltegravir treatment response in an HIV-2 infected patient: A case report. AIDS 2008;22(9): 1091-1092.
8. Damond F, Lariven S, Roquebert B, et al.: Virological and immunological response to HAART regimen containing integrase inhibitors in HIV-2-infected patients. AIDS 2008; 22(5):665-666.
9. Hazuda DJ, Miller MD, Nguyen BY, et al.: Resistance to the HIV-integrase inhibitor raltegravir: Analysis of protocol 005, a Phase II study in patients with triple-class resistant HIV-1 infection. Antiviral Ther 2007;12:S10 (Abstract 8).
10. Cooper DA, Steigbigel RT, Gatell JM, et al.: Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection. N Engl J Med 2008;359(4):355-365.
11. Charpentier C, Karmochkine M, Laureillard D, et al.: Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy. HIV Med 2008;9(9): 765-770.
12. Malet I, Delelis O, Valantin MA, et al.: Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother 2008;52(4):1351-1358.
13. McColl DJ, Fransen S, Gupta S, et al.: Resistance and cross-resistance to first generation integrase inhibitors: Insights from a phase II study of elvitegravir (GS-9137). Antiviral Ther 2007;12:S11 (Abstract 9).
14. Goethals O, Clayton R, Van GM, et al.: Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors. J Virol 2008;82(21):10366-10374.
15. Xu L, Hue S, Taylor S, et al.: Minimal variation in T-20 binding domain of different HIV-1 subtypes from antiretroviral-naive and -experienced patients. AIDS 2002;16(12):1684-1686.
16. Xu L, Anderson J, Ferns B, et al.: Genetic diversity of integrase (IN) sequences in antiretroviral treatment-naive and treatment-experienced HIV type 2 patients. AIDS Res Hum Retroviruses 2008;24(7):1003-1007.
17. Bacheler LT, Anton ED, Kudish P, et al.: Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 2000;44(9):2475-2484.
18. Roquebert B, Damond F, Collin G, et al.: HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro. J Antimicrob Chemother 2008;62(5): 914-920.
19. Rhee SY, Liu TF, Kiuchi M, et al.: Natural variation of HIV-1 group M integrase: Implications for a new class of antiretroviral inhibitors. Retrovirology 2008;5:74.
20. Jones G, Ledford R, Yu F, et al.: Resistance profile of HIV-1 mutants in vitro selected by the HIV-1 integrase inhibitor, GS-9137 ( JTK-303). Program and abstracts of the 14th Conference on Retroviruses and Opportunistic Infections, Los Angeles, California, Abstract 627, 2007.
21. Fikkert V, Hombrouck A, Van RB, et al.: Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360. AIDS 2004;18(15): 2019-2028.
22. Zahm JA, Bera S, Pandey KK, et al.: Mechanisms of human immunodeficiency virus type 1 concerted integration related to strand transfer inhibition and drug resistance. Antimicrob Agents Chemother 2008;52(9):3358-3368.
23. Marinello J, Marchand C, Mott BT, et al.: Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008;47(36):9345-9354.
24. Hombrouck A, Voet A, Van RB, et al.: Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137. Antimicrob Agents Chemother 2008;52(6):2069-2078.
25. Roquebert B, Blum L, Collin G, et al.: Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen. AIDS 2008;22(15):2045-2046.
26. Shimura K, Kodama E, Sakagami Y, et al.: Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir ( JTK-303=GS-9137). J Virol 2008;82(2):764-774.
27. Lecossier D, Shulman NS, Morand-Joubert L, et al.: Detection of minority populations of HIV-1 expressing the K103N resistance mutation in patients failing nevirapine. J Acquir Immune Defic Syndr 2005;38(1):37-42.
28. Charpentier C, Dwyer DE, Mammano F, et al.: Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J Virol 2004;78(8):4234-4247.